Asthma Management in Pregnancy

Primary Recommendation

Budesonide is the preferred inhaled corticosteroid for asthma management during pregnancy due to the most extensive safety data available in pregnant women, showing no increased risk of congenital malformations or adverse perinatal outcomes, as recommended by the American College of Allergy, Asthma, and Immunology 1, 2, 3
Budesonide should be the first-choice ICS when initiating inhaled corticosteroid therapy in pregnant women with persistent asthma, according to the National Asthma Education and Prevention Program 1, 2

Low-dose budesonide daily is the preferred long-term controller for mild persistent asthma in pregnant women, as recommended by the European Respiratory Society 1, 2, 5
Alternative agents, such as cromolyn, leukotriene receptor antagonists, and theophylline, are less effective than ICS and not preferred for pregnant women with mild persistent asthma 1, 3

Either low-dose budesonide plus long-acting beta-agonist or medium-dose budesonide is acceptable for moderate persistent asthma in pregnant women, according to the American College of Allergy, Asthma, and Immunology 1, 6, 5
The choice between these options depends on individual response and should be guided by the patient's healthcare provider 1

High-dose budesonide is preferred for severe persistent asthma in pregnant women, as recommended by the National Asthma Education and Prevention Program 7, 6, 5
Add systemic corticosteroids if high-dose ICS is insufficient, as severe uncontrolled asthma poses definite maternal-fetal risk, according to the European Respiratory Society 7, 6

Multiple international guidelines, including the National Asthma Education and Prevention Program and the European Respiratory Society, consistently recommend budesonide as the preferred inhaled corticosteroid for pregnant women with asthma 1, 2, 4
The FDA has specifically noted reassuring pregnancy data for budesonide, and beclomethasone is also considered an acceptable alternative 4

Never discontinue ICS during pregnancy due to safety concerns, as uncontrolled asthma poses far greater risk to mother and fetus than ICS use, according to the American College of Allergy, Asthma, and Immunology 5
Do not switch a well-controlled patient from another ICS to budesonide, as maintaining control is paramount, as recommended by the National Asthma Education and Prevention Program 1, 2
Do not undertreat exacerbations, as aggressive management with systemic corticosteroids when needed is safer than allowing maternal hypoxia, according to the European Respiratory Society 7, 5